Praxis Precision Medicines Clears FDA Hurdles for Two Key Drugs — Praxis Precision Medicines, Inc.

Event summary

FDA completed BIMO inspections for ulixacaltamide and relutrigine with no Form FDA 483 observations
Mid-cycle meetings for both drugs identified no major safety or efficacy concerns; no advisory committee meetings planned
Praxis received its third Breakthrough Therapy Designation for elsunersen in SCN2A DEE
Cash position of $1.4 billion as of June 30, 2026, provides runway into 2028

The big picture

Praxis Precision Medicines is positioning itself as a multi-product commercial company in the CNS space, with two key drugs advancing through regulatory milestones. The FDA's positive mid-cycle meetings and successful BIMO inspections reduce execution risk ahead of potential approvals. The company's strong cash position provides financial flexibility, but its ability to translate clinical progress into commercial success will be critical.

What we're watching

Regulatory Timelines: Whether the PDUFA dates for ulixacaltamide (January 29, 2027) and relutrigine (December 27, 2026) will hold without further delays.
Commercial Readiness: The pace at which Praxis can scale its commercial infrastructure ahead of potential approvals for ulixacaltamide and relutrigine.
Clinical Development: How the POWER2 study restart and EMBRAVE3 trial results will impact vormatrigine and elsunersen's development trajectories.